ArticleClinical drug investigation2019
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Jun Chen et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled itcites it